MCC950 as a promising candidate for blocking NLRP3 inflammasome activation: A review of preclinical research and future directions
Archiv der Pharmazie · 2024-11 · 357 (11)
DOI: 10.1002/ardp.202400459 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 23.08.2024. Verfasst von Yujia Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Jinghai, Tianjin, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Furans, Inflammasomes, Sulfonamides. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 341 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Tianjin City, China.
Abstract (Originalsprache)
The NOD‐like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome is a key component of the innate immune system that triggers inflammation and pyroptosis and contributes to the development of several diseases. Therefore, blocking the activation of the NLRP3 inflammasome has therapeutic potential for the treatment of these diseases. MCC950, a selective small molecule inhibitor, has emerged as a promising candidate for blocking NLRP3 inflammasome activation. Ongoing research is focused on elucidating the specific targets of MCC950 as well as assessfing its metabolism and safety profile. This review discusses the diseases that have been studied in relation to MCC950, with a focus on stroke, Alzheimer's disease, liver injury, atherosclerosis, diabetes mellitus, and sepsis, using bibliometric analysis. It then summarizes the potential pharmacological targets of MCC950 and discusses its toxicity. Furthermore, it traces the progression from preclinical to clinical research for the treatment of these diseases. Overall, this review provides a solid foundation for the clinical therapeutic potential of MCC950 and offers insights for future research and therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Jinghai, Tianjin, China.
- School of Medicial Technology, Tianjin University of Traditional Chinese Medicine, Tianjin, Jinghai, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City, China
Zitieren
APA
Zheng, Y., Zhang, X., Wang, Z., Zhang, R., Wei, H., Yan, X., Jiang, X., & Yang, L. (2024). MCC950 as a promising candidate for blocking NLRP3 inflammasome activation: A review of preclinical research and future directions. Archiv der Pharmazie, 357(11). https://doi.org/10.1002/ardp.202400459
Vancouver
Zheng Y, Zhang X, Wang Z, Zhang R, Wei H, Yan X, et al. MCC950 as a promising candidate for blocking NLRP3 inflammasome activation: A review of preclinical research and future directions. Archiv der Pharmazie. 2024;357(11). doi:10.1002/ardp.202400459
BibTeX
@article{Zheng2024,
author = {Zheng, Yujia and Zhang, Xiaolu and Wang, Ziyu and Zhang, Ruifeng and Wei, Huayuan and Yan, Xu and Jiang, Xijuan and Yang, Lin},
title = {MCC950 as a promising candidate for blocking NLRP3 inflammasome activation: A review of preclinical research and future directions},
journal = {Archiv der Pharmazie},
year = {2024},
volume = {357},
number = {11},
doi = {10.1002/ardp.202400459}
}
EUVIMED